India Medtronic Private Limited, a subsidiary of Medtronic plc (NYSE:MDT), has announced India’s pioneering NeuroSmart™ Portable Micro Electrode Recording (MER) Navigation system, aimed at enhancing Deep Brain Stimulation (DBS) therapy for Parkinson’s disease. This cutting-edge technology marks a significant milestone in neurological treatment, offering precise electrode placement to manage symptoms effectively.
DBS is a crucial therapy for Parkinson’s, addressing symptoms like tremors and stiffness. The NeuroSmart™ system enhances DBS precision during surgery, revolutionizing treatment outcomes. Developed by Alpha Omega Engineering, this system employs advanced neurophysiological navigation mapping, ensuring accurate electrode placement while recording neural activity. Its HaGuide automatic navigation identifies optimal targets, ensuring maximum symptom relief. Fortis Hospital Bengaluru’s Neurology team, led by Dr. Raghuram G and Dr. Guruprasad Hosurkar, pioneered the system’s debut on Parkinson’s patients. Their success with a 68-year-old patient showcased the technology’s efficacy in managing debilitating symptoms.
Dr. Raghuram G emphasized the system’s game-changing potential, attributing improved patient outcomes to enhanced precision. Dr. Guruprasad Hosurkar highlighted DBS therapy’s transformative impact on patients’ lives, now amplified by the advanced AI-enabled MER Navigation system. Prateek Tiwari, Senior Director at Medtronic India, emphasized the company’s commitment to innovation in DBS therapy, spanning over two decades. The NeuroSmart™ system seamlessly integrates into existing procedures, offering real-time feedback for enhanced accuracy and reliability.
